Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Clinical Lab Management › LabCorp's Covance Licenses Genfit's NASH Test

LabCorp's Covance Licenses Genfit's NASH Test

Jan 03, 2019
|
staff reporter

NEW YORK (360Dx) – Laboratory Corporation of America announced today that its Covance drug development business has signed a licensing agreement with Genfit to use a non-alcoholic steatohepatitis liver diagnostic (NASH) assay in the clinical research market.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14
Featured Webinar

Development of a Metagenomics-based Pathogen-Detection Assay for SARS-CoV-2 Research

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Clinical Lab Management

  1. Laboratory Stakeholders Including AMP, AACC Ask White House to Address COVID-19 Supply Chain Issues

  2. Clinical Mass Spec Sees Shakeup as Sciex Shuts Down Topaz, Thermo Launches Cascadion in US

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.